Design and engineering of capsid modified AAV-Based vectors targeted towards angiogenic and proliferating vasculature
Year: 2007
Type: article
Abstract: Cancer and cardiovascular disease are two leading causes of mortality in the United States.These two seemingly different diseases share the process of vascular proliferation or angiogenesis.Angiogenesis is the formation of new blood vessels through branching of pre-existing ones, and is essential for tumors to grow larger than 2-3mm and promotes tumor metastasis.In cardiovascular disease, angiogenesis can occur in response to damaged or ischemic tissue in an attempt to reestablish the blood supply or can be a cause of morbidity as in diabetic retinopathy.Vascular proliferation can also cause problems in pre-existing vasculature, for example in post-angioplasty restenosis.The purpose of this project is to specifically target damaged, proliferating, and angiogenic vasculature for gene therapy.Depending on the gene delivered, our long-term goal is to down-regulate proliferation, enhance angiogenesis, or destroy tumors and tumor vasculature through generation and use of novel targeted recombinant adenoassociated viral (rAAV) vectors.Adeno-associated virus (AAV) has garnered considerable interest as a gene therapy vector due to its ability to transduce a wide variety cells.Unfortunately, some cell types, including cells of the vasculature, remain refractive to AAV-mediated gene transduction.In attempts to increase transduction several groups have generated AAV particles with genetically modified capsids.Small peptides that bind to the cells of i x
Author: Matthew D. Stachler
Institution: The Ohio State University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2518822404